Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial
The highest tolerated dose of OTR4132 was the highest dose administered (i.e., 2.5 mg). These safety results need to be confirmed in a larger multicenter randomized placebo-controlled clinical trial. The trial was first registered in clinicaltrials.gov on 5 September 2019 (NCT04083001).
Authors
- Francisco Moniche (ORCID: https://orcid.org/0000-0001-8613-2909)
- Catherine Oppenheim (ORCID: https://orcid.org/0000-0003-3410-0862)
- Agnès Choppin (ORCID: https://orcid.org/0000-0002-3910-0282)
- Olivier Detante (ORCID: https://orcid.org/0000-0001-8761-3288)
- Olivier Heck
- Charlotte Rosso (ORCID: https://orcid.org/0000-0001-7236-1508)
- Igor Sibon (ORCID: https://orcid.org/0000-0002-1171-4215)
- Franck Chiappini (ORCID: https://orcid.org/0000-0002-2684-1241)
- Denis Barritault (ORCID: https://orcid.org/0000-0002-5584-8717)
- Xavier Barreau
- Martin Inizan
- Frédéric Sedel
- René Anxionnat
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- OTR3 (France) (FR)
- Société Française de Médecine Vasculaire (FR)
- Hôpital Pellegrin (FR)
- Imagerie Adaptative Diagnostique et Interventionnelle (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut de Psychiatrie et Neurosciences de Paris (FR)
- Instituto de Biomedicina de Sevilla (ES)
- Grenoble Institute of Neurosciences (FR)
- Hospital Universitario Virgen del Rocío (ES)
- Université Grenoble Alpes (FR)
- Université de Lorraine (FR)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1007/s40261-025-01487-y
- Citations
- 1
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- European Commission
- Horizon 2020 Framework Programme